Back to today’s briefing

Story perspectives

Goldman Sachs Warns: Gene Therapy's Revenue Risks Loom

11/16/2025

35 4

Summary

Story summary

Goldman Sachs analyst Salveen Richter highlights challenges of gene therapy and gene editing with "one shot cures" that could threaten biotech revenue.
Richter notes Gilead Sciences' hepatitis C treatments peaked at $12.5 billion in 2015 and may fall below $4 billion this year.
The report says revenue risk is lower in stable pools, such as cancer.
It also proposed three potential solutions for biotech firms facing these challenges.

1 of 1

Story summary

Goldman Sachs analyst Salveen Richter highlights challenges of gene therapy and gene editing with "one shot cures" that could threaten biotech revenue.
Richter notes Gilead Sciences' hepatitis C treatments peaked at $12.5 billion in 2015 and may fall below $4 billion this year.
The report says revenue risk is lower in stable pools, such as cancer.
It also proposed three potential solutions for biotech firms facing these challenges.